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Early events, including the identification of the cellular receptor, have not yet been described for adeno-associated virus
(AAV) infection. In this study, the binding characteristics of AAV-2 to human cells were examined in two different assays.
In a liquid-phase assay, in which binding of biotinylated virus to cells in suspension was measured, AAV-2 showed specific
binding to four different permissive cell lines: HeLa S3, 293, D6, and KB cells. In contrast, AAV-2 binding to erythrocytes
or to the nonpermissive cell line UT-7/Epo was negligible. AAV-2 binding showed saturation kinetics. Both binding and
infectivity of AAV-2 were abolished by trypsin treatment of cells, with significant recovery of bindings after 8 hr of culture,
suggesting that virus attachment occurs through a protein that can be regenerated on the cell surface. In a second, virus
overlay assay, we assessed binding of [35S]methionine-labeled AAV-2 to membrane proteins that had been transferred to
nitrocellulose after electrophoretic separation. In this assay, virus attachment was shown to a 150-kDa protein. This protein
was present in membranes from the AAV-2 permissive cell lines but not detected in membranes from erythrocytes or UT-
7/Epo cells. Enzymatic deglycosylation studies suggested that N-linked glycans are required for AAV-2 binding. A 150-kDa
glycoprotein might serve as the cellular receptor for AAV-2. q 1996 Academic Press, Inc.
INTRODUCTION However, when no helper virus is available, AAV infection
results in efficient integration of the AAV genome into
Adeno-associated viruses (AAV) are helper-dependent
the host cell genomic DNA. Integration appears to be
parvoviruses (dependovirus genus of the Parvoviridae),
preferentially targeted to a 100-nucleotide region on hu-
which originally were thought to replicate only in the
man chromosome 19 (Kotin et al., 1990, 1991; Samulski
presence of a co-infecting helper adeno- or herpes virus
et al., 1991; Giraud et al., 1994). The combined features
(Siegl et al., 1985; Carter, 1990a). However, recent stud-
of high efficiency of gene transfer and expression, inte-
ies have shown that AAV can also replicate in synchro-
gration into host cell genome, and apparent lack of
nized cells in some circumstances (Yakobson et al.,
pathogenicity have made AAV-2 a popular candidate as
1987). AAVs have been isolated from a variety of different
a viral vector for gene therapy (Muzyczka, 1992; Carter,
species, including primates, dogs, cows, horses, chick-
1992).
ens, and sheep (Siegl et al., 1985), and at least three
In contrast to the many studies on AAV-2 replication,
human AAVs have been described, but most studies on
very little is known about the initiating events of infection,
AAV growth, replication, and molecular biology have
including the identity of the AAV-2 cellular receptor. The
been undertaken using the nonpathogenic human ad-
cellular receptor is thought to be a ubiquitous molecule,
eno-associated virus type 2 (AAV-2). The virus has a sin-
as AAV-2 can infect a wide variety of human, simian, and
gle-stranded DNA genome of 4679 nucleotides (Srivas-
rodent cell lines provided the appropriate helper virus is
tava et al., 1983; Cassinotti et al., 1988; Ruffing et al.,
present (Cukor et al., 1984).
1994), with identical double-stranded hairpin structures
In this report we describe AAV-2 binding to cell surface
at both ends (Rose et al., 1969). Characteristically,
protein. Although the identity of this glycoprotein is still
strands of both polarities are encapsidated with equal
uncertain, its distribution among cells and cell lines cor-
efficiency (Berns and Rose, 1970; Rose et al., 1969). The
relates with infectivity, suggesting that this molecule
genome contains three transcriptionally active promot-
serves as the cellular receptor for AAV-2.
ers, from which mRNAs for four nonstructural (Rep) pro-
teins and three capsid (Cap) proteins are transcribed
MATERIALS AND METHODS(Mendelson et al., 1986; Cassinotti et al., 1988).
In the presence of helper virus, AAV undergoes a lytic
Cells and viruses
infection with production of infectious progeny virus.
Suspension cultures of HeLa S3 cells were maintained
in F12 medium with 7.5% fetal calf serum (FCS). The UT-1 To whom correspondence and reprint requests should be ad-
7/Epo cell line was provided by Dr. N. Komatsu (Jichidressed at Bldg. 10/Room 7C103, NIH, 9000 Rockville Pike, Bethesda,
MD 20892-1652. Fax: (301) 496-8396. Medical School, Japan) and maintained as described ear-
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lier (Komatsu et al., 1993). Adherent cell lines Detroit 6, [35S]Methionine labeling of AAV-2 capsids
293, and KB were grown as previously reported (Carter
AAV-2 capsids were labeled by methionine depletion,et al., 1979; Hermonat et al., 1984), and the monolayer
followed by a pulse of [35S]methionine and later adjust-was physically dispersed to separate the cells before use
ment of the methionine concentration. The time coursein the binding assays. Erythrocytes (O, Rhesus negative)
for the pulse was determined from earlier reports whichwere obtained from healthy volunteers.
showed that the maximum rate of viral DNA, protein syn-AAV-1, AAV-2, AAV-3, and adenovirus type 2 (Ad.2)
thesis, and particle assembly occurs 10–30 hr after AAV-were obtained from the American Type Culture Collection
2 inoculation (Carter et al., 1973; Carter, 1990b).(ATCC). Stock preparations of AAV-2 virions were pre-
KB cells were co-infected with AAV-2 and adenoviruspared by simultaneous co-infection of KB cells with AAV-
type 2 and the cells cultured in Dulbecco’s minimal es-2 and the adenovirus, and the cells were harvested 40
sential medium (DMEM) with 2% FCS for 12 hr. Cellshr later. Virus was prepared as previously described
were washed in PBS, the culture medium changed to(Berns and Rose, 1970), followed by three cycles of ce-
DMEM without methionine (Biofluids, Inc.) but containingsium chloride purification (Rose et al., 1966). Quantifica-
2% dialyzed FCS, and the cells incubated for a further 2tion of the AAV-2 virions was determined by measuring
hr. Medium was supplemented with [35S]methioninethe protein content (BCA method, Pierce Chemical Co.)
(37 TBq/mmol, cell-labeling grade, Amersham, finalof the purified virus preparations. Stock preparations of
concentration 1.85 MBq/ml) for 30 min, and then the con-AAV-1 and AAV-3 were made as described (Rose et al.,
centration of nonlabeled methionine was readjusted to1971) and purified as for AAV-2.
30 mg/liter. The cells were incubated for a total of 40 hr
following virus adsorption and AAV-2 particles purified
Cell permissivity for AAV-2 as for nonlabeled virus.
Cell permissivity for AAV-2 was determined by immu-
Liquid-phase binding assaynofluorescence (Carter et al., 1979) with minor modifica-
tions. Briefly, one million HeLa S3, KB, and UT-7/Epo Biotinylated AAV-2 virions were mixed with cells in
cells were infected by adenovirus type 2 (1 PFU per cell) 500 ml 0.05% Tween 20–phosphate-buffered saline
with or without AAV-2 (1 TCID50 per cell). Cells were fixed (PBST) containing 1% bovine serum albumin (BSA) and
in 1:1 acetone/methanol for 10 min at 0207 40 hr after incubated for 1 hr at 47 with constant shaking. Unbound
infection and stained by either rabbit anti-adenovirus virus was removed by washing the cells three times with
type 2 (ATCC) or guinea pig anti-AAV-2 (ATCC). Incuba- PBST and centrifugation. The cellular pellets were resus-
tion with primary antibodies diluted 1:200 in PBS con- pended by 1% BSA–PBST with 100 ng of [125I]streptavidin
taining 10% FCS for 1 hr at 257 was followed by washing (specific activity 0.74–1.5 MBq/mg, Amersham) for 1 hr
in PBS and incubation with antispecies FITC-conjugated at 47. The cells were rewashed with PBST and centri-
second antibodies (1:100 dilution) for 1 hr at 257. Cells fuged, prior to resuspension in 10 ml scintillation fluid
then were washed in PBS and visualized under a UV and measurement of the bound radioactivity in a Beck-
microscope. man LS6500 scintillation counter. Nonspecific binding
of biotinylated AAV-2 was determined by measuring the
Biotinylation of AAV-2 capsids radioactivity of identical samples in the presence of a
30-fold excess of nonbiotinylated virions. In subsequent
AAV-2 capsids were biotinylated using N-hydroxysuc- experiments, two other AAVs, AAV-1 and AAV-3, were
cinimide–biotin ester (Amersham), according to the man- used to compete with labeled AAV-2 to see whether
ufacturer’s instructions. Briefly, 4 ml of biotinylation re- these dependoviruses share the same receptor site.
agent was mixed with 100 mg of AAV-2 virion preparation,
the mixture was incubated at 257 for 1 hr with constant Trypsinization of cells
shaking, and biotinylated virions were dialyzed against
PBS for 12 hr. The incorporation of biotin into AAV-2 Trypsin treatment of cells was performed as previously
described (Philipson et al., 1968) with minor modifica-virions was assessed by Western blotting of the viral
protein, with detection of AAV capsid proteins with either tions. Briefly, 107 cells were suspended in 1 ml of 0.1%
of trypsin (ABI) in PBS containing 0.02% EDTA and incu-guinea pig anti-AAV-2 antibody (ATCC) or horseradish
peroxidase-conjugated streptavidin (Amersham). The bated at 377 for 10 min. Cells were washed twice in
culture medium containing 7.5% FCS and either testedproportion of nonbiotinylated virions was assessed by
the removal of biotinylated virions with immobilized immediately or resuspended in culture medium and
grown in tissue culture for a further 8 hr before assay ofstreptavidin prior to Western blotting. Structural integrity
of the biotinylated AAV-2 was assessed by infectivity AAV-2 binding.
Trypsinized cells were also examined for permissivityassays through immunofluorescence. Biotinylated AAV-
2 was used within 2 weeks of preparation. to AAV-2 infection. One million HeLa S3 cells were first
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infected by adenovirus type 2 (1 PFU per cell). Ten hours RESULTS
later, trypsin treatment was performed as stated above,
UT-7/Epo cells are nonpermissive for AAV-2
followed by an inoculation of AAV-2 (1 TCID50 per cell).
Cells were fixed at 40 hr postinfection of adenovirus 2 HeLa S3, KB, and UT-7/Epo cells could be infected by
adenovirus type 2 (Table 1), indicating that these celland evidence for AAV-2 infection was assayed as above.
lines support helper virus replication. However, AAV-2
infectivity assays showed that UT-7/Epo cells could notVirus overlay binding assay
be infected by AAV-2 (Table 1). As previously described,
we confirmed that HeLa S3 and KB cells were permissiveSuspended cells were washed in PBS and disrupted
by Dounce homogenization in the presence of a mixture for AAV-2 infection (Table 1).
of protease inhibitors (Kajigaya et al., 1989), and mem-
Biotinylation of AAV-2 does not affect binding/brane fractions prepared as previously described (Chong
infectivityand Rose, 1993; Bergmann and Fusco, 1988). Human
erythrocyte membranes were prepared as red cell ghosts Biotinylation of AAV-2 virions resulted in a slight in-
(Dodge et al., 1963). crease (by 1–2 kDa) in the apparent molecular weight
The membrane fractions (500 mg of protein) were elec- for each capsid protein (VP1, VP2, and VP3) as assessed
trophoresed on 5% polyacrylamide gels with sodium do- by Western blotting, and all three proteins were detected
decyl sulfate (SDS) under standard denaturing conditions with [125I]streptavidin (data not shown). Nonbiotinylated
(Laemmli, 1970) and electrophoretically transferred to a virions were not detectable after removal with immobi-
nitrocellulose sheet (Schleicher & Schuell) (Towbin et al., lized streptavidin. Biotinylation did not affect virus infec-
1979). Nonspecific binding sites were blocked by incu- tivity as assessed by immunofluorescence (data not
bating the nitrocellulose membrane in PBST with 5% BSA shown).
for 2 hr at room temperature. The membrane was cut
into 25 strips of about 3 mm width and each strip incu- Analysis of AAV-2 binding to human cells
bated with 1 1 1012 particles of 35S-labeled AAV-2 virions
In these studies, 3 1 1010 biotinylated AAV-2 virionsin 2 ml PBST with 1% BSA for 2 hr at room temperature
were incubated with 105 cells for 1 hr at 47. Binding ofon a rotary shaker. The strips were washed for 10 min
AAV-2 was demonstrated with the cell lines HeLa S3,in PBST three times to remove unbound virus, and the
293, KB, and Detroit 6 which are known to be permissivebound virus was detected using the Phosphor Imager
to AAV-2 (Fig. 1). Binding was decreased in the presencesystem (Molecular Dynamics).
of a 30-fold excess of nonbiotinylated virions, indicating
that the AAV-2 binding was specific. In contrast, there
Two-dimensional analysis for virus overlay binding was no detectable binding to erythrocytes or to the non-
permissive megakaryocytic cell line UT7/Epo.Membrane fractions (500 mg of protein per gel) were
first analyzed by isoelectric focusing using a 1.5-mm tube
Specificity of the AAV-2 binding
gel system with ampholytes (pH range 3.5–9.5, Phar-
macia Biotech), followed by conventional SDS–PAGE us- HeLa S3 cells (21 104) were incubated with increasing
amounts of biotinylated AAV-2, and a dose–responseing 5% polyacrylamide gel as second dimension (O’Far-
rell, 1975; Anderson, 1991). Proteins were electrically curve was constructed (Fig. 2). As above, binding of bio-
tinylated virions in the presence of a 30-fold excess oftransferred and reacted with 35S-labeled AAV in the same
way as for virus overlay assays. nonbiotinylated virions was used to assess nonspecific
binding. (In contrast to the above experiments, lower cell
numbers were used to increase the virion:cell ratio). TheEnzymatic deglycosylation
amount of nonspecific binding at high concentrations of
virus was low, less than 10% of total binding. In contrast,Recombinant deglycosylation enzymes N-acetylneur-
aminidase II (NANase II), O-glycosidase DS, and peptide total binding rose with increased viral input, with evi-
dence suggestive of a plateau at the highest concentra-N-glycosidase F (PNGase-F) were used in combination
according to the manufacturer’s instructions (GLYKO). tion (2 1 1011 virions or 107 virions/cell), which would
be consistent with saturable binding. Binding of higherBriefly, 50 mg of membrane protein was dissolved in 20 ml
of 50 mM sodium phosphate, pH 6.0, and deglycosylated concentrations of virus would clarify whether the binding
was truly saturable, but the required amount of virus,with 10 mU NANase II, 5 mU O-glycosidase, and 5 mU
PNGase-F. Protease inhibitors were included throughout with the 30-fold excess to test for binding specificity, was
practically unattainable by current methodology.the reaction (Kajigaya et al., 1989). Following deglycosyl-
ation, the membrane fractions were electrophoresed, In experiments with other AAVs, AAV-1 and AAV-3 did
not shown competition with biotinylated AAV-2 (Fig. 3),transferred to nitrocellulose, and tested in the virus over-
lay assay. suggesting that this assay is specific and also that AAV-
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TABLE 1
Immunofluorescence of UT-7/Epo Cells
Cell lines Antibody Noninfected Ad.2 alone Ad.2 / AAV-2
HeLa S3 Anti-Ad.2 0 / /
Anti-AAV-2 0 0 /
KB Anti-Ad.2 0 / /
Anti-AAV-2 0 0 /
UT-7/Epo Anti-Ad.2 0 / /
Anti-AAV-2 0 0 0
Note. Cells were infected by Ad.2 with or without AAV-2, cultured for 40 hr, then fixed and stained by primary antibody, followed by FITC-labeled
secondary antibody. ‘‘/’’ and ‘‘0’’ indicate positivity and negativity in immunofluorescence.
1 and AAV-3 do not share the same receptor site with AAV-2 binds to a 150-kDa protein
AAV-2.
[125I]Streptavidin bound directly to some membrane
proteins after SDS–PAGE, and therefore [35S]methionine-
Sensitivity of AAV-2 binding and permissivity to labeled AAV-2 virions were used for the virus overlay
trypsin treatment binding assay. The [35S]methionine-labeled virions had a
specific activity of 1.5 1 104 cpm/mg or 1 1 1007 cpm/
To determine whether the AAV-2 cellular receptor was virion. Membrane fractions were prepared from four AAV-
a protein, HeLa S3 cells were subjected to trypsin treat- 2 permissive cell lines, HeLa S3, 293, KB, and Detroit 6.
ment before testing in the liquid binding assay. Cell via- All four preparations showed binding of AAV-2 virions to
bility was not impaired by this treatment (as assessed a single band, corresponding to a protein of approxi-
by dye exclusion). Pretreatment of the cells with trypsin mately 150 kDa (Fig. 4). There was no significant binding
almost completely abolished the binding of AAV-2, and to any other bands. (Binding was also observed to the
there was no evidence of specific AAV-2 binding (Fig. 3). electrophoresis ‘‘front,’’ but there were no specific bands
Eight hours after treatment there was significant recovery visualized, even when 12% polyacrylamide gels were
of AAV-2 specific binding, suggesting regeneration of the used for separation.) When erythrocytes or UT7/Epo cells
AAV-2 binding protein. were used as the source of membrane no specific bind-
Trypsinized HeLa S3 cells were also examined for per- ing was observed (Fig. 4).
missivity to infection by AAV-2. In contrast to the un- To characterize the virus binding properties further,
treated cells, cells after trypsin treatment no longer sup-
ported AAV-2 infection (Table 2). These results suggest
that cellular attachment of AAV-2 requires a membrane
protein.
FIG. 1. Liquid-phase bindings of AAV-2 to different cell types. Within
Eppendorf tubes, 1 1 105 cells were incubated with 3 1 1010 biotinyl-
ated AAV-2 in the absence or presence of cold virus. Binding was FIG. 2. Bindings of biotinylated AAV-2 on HeLa S3 cells. 2 1 104
HeLa S3 cells were reacted with various amounts of virions. j indicatedetected with [125I]streptavidin. j indicate total binding. h indicate
binding in the presence of a 30-fold excess of nonbiotinylated virions. total binding. h indicate binding in the presence of a 30-fold excess
of nonbiotinylated virions. All experiments were performed in triplicateExperiments were performed in triplicate and bars indicate the stan-
dard error of the mean (SEM). and bars indicate SEM.
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FIG. 3. Inhibition of AAV-2 binding by the presence of other AAVs.
Liquid-phase bindings were performed as in Fig. 1 with 30-fold excess
of (A) AAV-1 or (B) AAV-3. Results with AAV-2 are also shown, and the
100% binding indicates the binding without the use of cold viruses.
FIG. 4. Effect of trypsin treatment. HeLa S3 cells (1 1 107) weremembrane fractions from permissive cell lines were ana-
treated with trypsin (0.1%, 377 for 10 min), washed, and used in thelyzed by two-dimensional electrophoresis prior to trans-
liquid binding assay (1 1 105 cells with 3 1 1010 biotinylated virions).fer. For both HeLa S3 and 293 cells, we observed bind-
Cells with no treatment, immediately after treatment, and 8 hr after
ings of labeled virus to several protein bands with pI treatment were tested. j indicate total binding. h indicate binding in
levels between 4.5 and 5.0 and molecular weight of 150 the presence of a 30-fold excess of nonbiotinylated virions. Experiments
were performed in triplicate and bars indicate SEM.kDa (Figs. 5a and 5b). Binding to the electrophoretic front
was not separable by isoelectric focusing, suggesting
that this activity was not directed to a protein. mediated by the binding of a protein on the viral surface,
the viral attachment protein, to a molecule on the cellSensitivity of AAV-2 binding to deglycosylation
membrane acting as the virus cellular receptor. Virus
HeLa S3 membrane preparations were treated with cellular receptors have been identified for only a few of
different deglycosylation enzymes, then subjected to viral the human viruses and for only one of the Parvoviridae
overlay assay. Treatment with O-glycosidase or NANase (Brown et al., 1993). To our knowledge this is the first
II did not affect binding to the 150-kDa band (Fig. 5), report to characterize a putative cellular receptor for any
although these enzymes clearly removed sugar moieties of the adeno-associated viruses.
from control glycoproteins (data not shown). However, Our results demonstrate that for the permissive cell
PNGase-F, which cleaves N-linked glycans from pro- lines HeLa S3, 293, Detroit 6, and KB, AAV-2 binds in a
teins, abolished AAV-2 binding in HeLa S3 cell lines (Fig. specific manner, with competition by unlabeled virus, and
6). Membrane proteins from 293 cells showed the same
results (data not shown). These results indicate that the
150-kDa band is a glycosylated protein and that the N-
linked sugar moieties are important for AAV-2 binding.
DISCUSSION
The first step in viral infection of a host cell is attach-
ment of the virus to the cell surface. This attachment is
TABLE 2
Immunofluorescence of Trypsinized HeLa S3 Cells
Antibody No treatment Trypsinized
Anti-Ad.2 / /
Anti-AAV-2 / 0
FIG. 5. Virus overlay binding assays upon various cells by 35S-labeled
virions. Twenty micrograms of membrane protein was used for eachNote. HeLa S3 cells were first infected by Ad.2. Ten hours later, cells
were treated by trypsin, then infected by AAV-2. Cells were fixed at 40 strip. Membrane proteins were electrophoresed on 5% polyacrylamide
gel, transferred to a nitrocellulose sheet, then reacted with 1012 parti-hr after Ad.2 infection and stained by primary antibody, followed by
FITC-labeled secondary antibody./ and0 indicate positivity and nega- cles of [35S]methionine-labeled AAV-2 for 2 hr. Molecular weight mark-
ers are shown for each set of gels marked as a, b, and c.tivity in immunofluorescence.
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than antigenicity. We are in the process of sequencing
these viruses to further investigate the differences be-
tween them.
In contrast to the quantitative nature of the liquid-
phase binding assay, the virus overlay assay, a variant
of Western blotting, is qualitative. Whereas measured
numbers of cells are assayed in the liquid test, purified
cell membranes are used for virus overlay. The virus
overlay assay was used to confirm binding patterns and,
more important, yielded information on the size and gly-
cosylation of the binding protein. Virus overlay assays
have been used to characterize a number of different
virus cellular receptors, including the mouse hepatitis
virus receptor (Boyle et al., 1987), but they require that
the receptor is a protein. The susceptibility of the AAV-
2 binding to trypsin treatment indicated that the AAV-2
receptor was a protein and this was confirmed by the
virus overlay binding assays. AAV-2 bound to a 150-kDa
protein only present in membrane preparations from per-
missive cells and not in preparations from erythrocytes
or UT-7/Epo cells. In addition, the virus overlay assay
FIG. 6. Two-dimensional analysis of virus overlay binding assays. was used to show that binding was mediated through the
Five hundred micrograms of membrane proteins was treated by iso- involvement of N-linked glycans. The enzyme PNGase-F
electric focusing under 9.0 M urea, 2.0% NP-40, and 2% ampholytes
clearly removed the binding observed at 150 kDa. This(pH range 3.5–9.5), followed by 5% SDS–PAGE. After second-dimen-
effect is unlikely to be caused by endogenous proteolyticsion run, proteins were transferred to a nitrocellulose sheet, then re-
acted as virus overlay binding assays. (A) HeLa S3 cells, (B) 293 cells. activities of the membrane fractions because a cocktail
of protease inhibitors were included throughout the reac-
tion, and samples kept at 377 without enzymes showed
that the binding shows saturation kinetics. In contrast, no decrease in binding (Fig. 7). In addition, the deglyco-
there was no binding to negative control cells, human sylation enzymes used were recombinant and hence free
erythrocytes, and UT-7/Epo cells. Red blood cells were of contaminating proteases (Tarentino et al., 1990). Two-
used as negative control on the basis of absent hemag- dimensional analysis of this protein showed multiple
glutination (Hoggan, 1971). UT-7/Epo cells were tested bands at a single molecular weight but of varying pI,
because this cell line has erythroid characteristics; the consistent with different glycoforms of a single protein.
cell line requires erythropoietin for its survival and growth The putative receptor molecule has only been charac-
(Komatsu et al., 1993) and it can propagate parvovirus terized as a 150-kDa glycoprotein. Further studies are in
B19 which has erythroid cell tropism (Shimomura et al.,
1992). Infectivity assay suggests that this cell line is truly
nonpermissive to AAV-2. AAV-2 is believed to have a
wide host range and tissue tropism (Cukor et al., 1984),
and nonpermissive cells for AAV-2 have not been de-
scribed, although recently certain megakaryocytic cell
lines may also be nonpermissive for AAV-2 (Ponnazha-
gan et al., 1994). The UT-7/Epo cell line may be useful
for further receptor studies as a negative control.
As a further test of the specificity of the binding assay,
competition of binding was performed using two other
dependoviruses. The absence of competition by either
AAV-1 or AAV-3 suggests that the AAV-2 binding was FIG. 7. Effect of deglycosylation enzymes for virus overlay binding
specific and that these viruses do not share the cellular assays. Twenty micrograms of membrane proteins was used for each
receptor with AAV-2. Very little is known about the capsid strip. Membrane proteins were treated by enzymes followed by the
same procedures as in Fig. 4. Membrane proteins from HeLa S3 cellsstructure of these viruses, except that they have capsid
were treated as follows, then processed as virus overlay bindingproteins of similar molecular weight (Rose et al., 1971).
assays. Lane 1, no treatment. Lane 2, incubation at 377 throughout the
The suggestion that the viruses may use different cellular reaction period, but no enzymes. Lane 3, NANase II treatment. Lane
receptors for host cell entry indicates that there may 4, NANase II and O-glycosidase treatment. Lane 5, NANase II, O-
glycosidase, and PNGase-F treatment.be more fundamental differences between these viruses
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Okano, H., Katsube, T., Fukumaki, Y., Sassa, S., and Miura, Y. (1993).progress to isolate the protein for peptide sequencing
Establishment and characterization of an erythropoietin-dependentand to generate specific monoclonal antibodies to allow
subline, UT-7/Epo, derived from human leukemia cell line, UT-7.
further characterization. Identification of the receptor Blood 82, 456–464.
molecule will facilitate understanding of the early events Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X., Hunter, L., Laughlin,
C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., and Berns, K. I.of AAV-2 infection. In addition, the tissue distribution of
(1990). Site-specific integration by adeno-associated virus. Proc. Natl.the AAV-2 cellular receptor should elucidate the host
Acad. Sci. USA 87, 2211–2215.range and tissue tropism of AAV-2 and permit a more
Kotin, R. M., Menninger, J. C., Ward, D. C., and Berns, K. I. (1991).
informed approach in designing strategies for AAV-2-me- Mapping and direct visualization of a region-specific viral DNA inte-
diated gene therapy. gration site on chromosome 19q13-qter. Genomics 10, 831–834.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assem-
bly of the head of bacteriophage T4. Nature 227, 680.
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